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Beta amyloid peptides (Aβ) are found to be associated with dysfunction of
hypothalamic-pituitary-adrenal axis (HPA axis) that leads to memory and cognitive
deficits in patients with Alzheimer’s disease (AD). Phosphodiesterase 4 (PDE4) inhibitors
increase the intracellular cAMP activities, which may ameliorate cognitive deficits
associated with AD. However, it remains unclear whether PDE4-mediated reversal of
cognitive impairment in mouse model of AD is related to HPA axis and downstream
cAMP-dependent pathway. The present study investigated the effects of PDE4 inhibitor
rolipram on Aβ1-42-induced cognitive dysfunction and its underlying mechanisms.
The step-down passive avoidance (PA) and Morris water-maze (MWM) tests were
conducted 1 week (1 W), 2 months (2 M), and 6 months (6 M) after intracerebroventricular
microjection (i.c.v.) of Aβ1-42. The results suggested that memory impairment emerged
as early as 1 W, peaked at 2 M, and lasted until 6 M after injection. Chronic treatment with
rolipram (0.1, 0.5, 1.0 mg/kg/d, i.p.) for 2 weeks (i.e., treatment started at 1.5 months
after Aβ1-42 microinjection) dose-dependently improved memory performance in both
MWM and PA tests. Moreover, rolipram reversed the Aβ-induced increases in serum
corticosterone (CORT), corticotropin-releasing factor, and glucocorticoid receptors
(CRF-R and GR) levels, whereas it decreases in brain-derived neurotropic factor (BDNF)
and the ratio of pCREB to CREB expression. These effects of rolipram were prevented
by pre-treatment with PKA inhibitor H89. The findings indicated that the protective
effects of rolipram against Aβ1-42-induced memory deficits might involve HPA axis and
cAMP-CREB-BDNF signaling.
Keywords: Alzheimer’s disease, Aβ1-42, rolipram, learning and memory, Phosphodiesterases 4A, HPA axis
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INTRODUCTION

HPA axis dysfunction, and how PDE4 inhibition could enhance
memory through the regulation of HPA axis system.

Alzheimer’s disease (AD), the most common type of dementia, is
a progressive nervous system degenerative disease characterized
by subjective cognitive decline (SCD) and mild cognitive
impairment (MCI) (Heckman et al., 2015). The amyloid cascade
hypothesis has been considered as the central hypothesis for
the cause of AD, which suggests that memory deficits correlate
closely with cortical soluble beta amyloid (Aβ) oligomers and
protofibrils (Blennow et al., 2006). Two primary forms of Aβ,
such as Aβ1-42 and Aβ1-40, are recognized as disease markers
in AD patients. However, Aβ1-42 form is more neurotoxic
than the Aβ1-40 form, which mainly facilitates the progression
of the disease (Cheng et al., 2010). Recent studies suggested
that it is not sufficient to decrease the cerebral Aβ levels for
the purpose of preventing memory impairment because the
accumulation of beta amyloid or senile plaques is often comorbid
with increased neurofibrillary tangles (Ballard et al., 2011),
making the symptoms irreversible in the later period of the
disease. Therefore, early intervention with medicine is necessary
to counteract the progress of memory deficits and dementia.
The hypothalamic-pituitary-adrenal (HPA) axis is an intricate
arrangement of direct impacts and feedback interactions among
three endocrine glands, i.e., the hypothalamus, pituitary, and
adrenal glands. Increasing evidence suggests that animal models
with MCI experience moderately increased corticosterone levels
in serum, which indicate that dysfunction of the HPA axis
may lead to memory decline that occurs in early dementia
(Xu et al., 2009). Indeed, clinical studies have suggested that
cognitive dysfunctions (i.e., learning and memory deficits) and
psychological symptoms (i.e., irritation, depression, or anxiety)
in AD patients are related to an early disturbance of the HPA
axis (Brureau et al., 2013). However, whether such impacts
involve Aβ accumulation is still controversial (Green et al., 2006).
Our previous studies suggested that dysregulation of HPA axis
decreased the second messenger cyclic nucleotides, 3′ 5′ -cyclic
guanosine monophosphate (cGMP) and 3′ 5′ -cyclic adenosine
monophosphate (cAMP) (Xu et al., 2013, 2015), which are
important learning and memory mediators in various species
of animals (Lueptow et al., 2016). Therefore, targeting the
cyclic nucleotide phosphodiesterases (PDEs), the enzymes that
hydrolyze and inactivate these second messengers, is expected
to enhance cognition. PDE4, one of the PDE enzymes that
selectively hydrolyzes cAMP, is considered to be involved in
learning and memory processes (Richter et al., 2013). The
selective PDE4 inhibitor has a series of CNS effects including
antidepressant and memory-enhancing effects (Richter et al.,
2013). Recent study suggested that PDE4 inhibitor could
ameliorate the HPA axis dysfunction induced by stress (Jindal
et al., 2015), but studies linking dysfunction of HPA axis caused
by Aβ and treatment of PDE4 inhibitors are lacking.
In the present study, the serum corticosterone level,
glucocorticoid receptor (GR) and corticotropin-releasing
factor receptor (CRF-R) expression, phosphorylation of cyclic
AMP response element binding (pCREB), and brain-derived
neurotrophic factor (BDNF) levels were examined to clarify
whether Aβ1-42-induced pathological changes were related to
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MATERIALS AND METHODS
Animals
Adult male ICR mice (22–25 g) used for the experiments were
obtained from the Animal Center of Shanghai Branch, Chinese
Academy of Sciences. Mice were housed in a temperaturecontrolled room with the humidity of 50–60% and a 12-h
light/dark cycle and had free access to standard diet and water.
Mice were allowed an acclimation period for 5 days before the
experiments. All procedures were carried out in a quiet room
according to the “NIH Guide for the Care and Use of Laboratory
Animals” (NIH Publications No. 80-23, revised 1996) and were
approved by Committees of Wenzhou Medical University on
Animal Care and Use.

Surgery
The surgery for brain cannula implantation was performed
aseptically under xylazine (6 mg/kg) and ketamine (100 mg/kg)
anesthesia. The mice were placed in a stereotaxic apparatus
with flat-skull position and the head was kept horizontally. The
guide cannulas (30-gauge) were implanted bilaterally into the
intracerebroventricles (AP −0.2 mm from bregma, ML ± 1.0 mm
from midline, DV −2.5 mm from dura) (Wang et al., 2016) for
microinfusion. Three days after the surgery, 2 µl Aβ1-42 (0.4
µg/µl, 1 µl/side) or 0.9% sterile saline was infused bilaterally at
the rate of 0.25 µl/min using microinjection pump. To permit
diffusion after microinjection, the infusion cannulae were left in
place for an extra 5 min.

Chemicals and Drug Administration
Aβ1-42 (rPeptide, USA) was dissolved in 0.9 % sterile saline,
at a final concentration of 0.4 µg/µl, and incubated at 37◦ C
for 4 days to obtain aggregated Aβ before microinfusion into
cerebroventricle (Wang et al., 2012). Rolipram (Sigma-Aldrich,
USA) was prepared by being dissolved in 0.9% sterile saline
containing 1% dimethyl sulfoxide (DMSO). One and a half
months after microinjection with Aβ1-42, the mice were treated
with different doses of rolipram (0.1, 0.5, 1.0 mg/kg/day, i.p.) or
vehicle for 2 weeks. KT5823 (Cayman Chemical, USA), a selective
inhibitor of cGMP-dependent protein kinase (PKG), and H89
(Sigm-Aldrich, USA), a cAMP-dependent protein kinase (PKA),
were dissolved in artificial cerebrospinal fluid (ACSF) and were
bilaterally microinjected into the intracerebroventricular, 30 min
before treatment with rolipram.
The primary antibodies of anti-CRFR1, anti-BDNF, and
anti-GR were purchased from Abcam Biotechnology Company
(Abcam, Cambridge, MA). The anti-pCREB and anti-CREB were
purchased from Merck Milipore (Millipore,Billerica,MA,USA).
All the secondary antibodies (anti-rabbit lgG) were purchased
from MultiSciences Biotech Co., Ltd. (MultiSciences, Hangzhou,
China). The CORT ELISA kit was purchased from Enzo Life
Sciences (Enzo Life Sciences, USA).
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Behavioral Test Procedures

the electric shock of the grid was removed. The mouse was
individually placed on the wooden platform and the time of first
attempt to jump off the platform was recorded as step-down
latency, with an upper cut off time of 300 s (Nasehi et al., 2012).

Two experiments were included in this project. In experiment 1,
six groups of 10 mice each were used for measuring the learning
and memory performances in the Morris water maze and stepdown passive avoidance tests (MWM and PA). The six groups
are (1) control (1 W), (2) model (1 W), (3) control (2 M), (4)
model (2 M), (5) control (6 M), and (6) model (6 M). Experiment
2 was performed to investigate the effects of chronic treatment of
rolipram on short-term and long-term memory processes using
the MWM and PA tests. Specifically, seven groups of 10 mice
each were used for this experiment: (1) vehicle 1 (for Aβ1-42)
+ vehicle 2 (for rolipram), (2) Aβ1-42 + vehicle 2, (3) Aβ1-42
+ rolipram (0.1 mg/kg, i.p.), (4) Aβ1-42 + rolipram (0.5 mg/kg,
i.p.), (5) Aβ1-42 + rolipram (1.0 mg/kg, i.p.), (6) Aβ1-42 +
rolipram (1.0 mg/kg, i.p.) + KT5823 (20 µM, 1 µl/side), and
(7) Aβ1-42 + rolipram (1.0 mg/kg) + H89 (5 µM, 1 µl/side).
They were injected drugs once daily for 2 weeks before MWM
and PA tests, i.e., 1.5 months after i.c.v. injections of Aβ1-42.
H89 (5 µM, 1 µl/side) and KT 5823 (20 µM, 1 µl/side) were
given 30 min before treatment with rolipram. H89 and KT5823
used alone did not show any effects, which were summarized in
Supplementary Figures 1, 2.

Serum Corticosterone Measurement
The serum level of CORT was assessed by ELISA assay based on
the manufacturer’s instructions. Following behavioral testing, the
mice were decapitated and the trunk blood was collected, the
plasma was removed by centrifuging at 3,000 rpm for 10 min
(Xu et al., 2013). In order to rule out the potential effects of
diurnal rhythm on mouse hormone levels, all blood samples were
collected at 4:00–6:00 pm.

Immunoblotting Analysis
Mice were decapitated following the behavioral tests. The brain
tissues including the hippocampus and prefrontal cortex were
dissected and immediately stored at −80◦ C until analysis. They
were then thawed and subsequently homogenized in RIPA
lysis buffer containing protease and phosphatase inhibitors and
centrifuged at 14,000 rpm for 20 min at 4◦ C for the measurement
of protein. Protein concentrations were determined using the
BCA protein assay (Chen et al., 2011). Samples (60 µg protein
each) were separated using SDS-PAGE before transferring to
PVDF membranes (0.20 µm; Millipore, Billerica, MA, USA).
Nonspecific bindings were blocked with 5% skim milk for 90 min.
Membranes were subsequently incubated with the appropriate
primary antibodies for rabbit anti-GR (1:5,000), anti-CRF-R
(1:5,000), anti-pCREB (1:1,000), anti-CREB (1:500), anti-BDNF
(1:2,000), and anti-β-Actin (1:1,000) overnight at 4◦ C. After
washing with TBST (0.1%) and incubation with secondary
antibodies, ECL kit was used to visualize the immune complex
by chemiluminescence. The specific bands were detected using
GelDoc XR System (Bio-Rad, USA) and quantified using
Quantity One software.

Morris Water Maze Test (MWM)
The MWM test was conducted as described earlier (Xu et al.,
2015). The circular pool was filled with opaque water (21 ± 1◦ C).
A hidden circular platform (8.5 cm diameter and 15.5 cm high)
was submerged 2 cm under the surface of water in the fourth
quadrant. The acquisition trials were carried out for six learning
blocks before the probe trial and separated by 20 min intervals.
Each block includes 3 trials, during which the mice were placed
in the apparatus from the first, second, or third quadrant. Mice
were guided to the platform manually unless they escaped to
the hidden platform. During the acquisition trials, the platform
was invisible in the similar area relative to the distal cues in the
room. The probe trial was conducted 1 and 24 h after the training
session to measure the spatial memory, in which the platform
was removed. During the probe trial, mice were placed in the
apparatus from the second quadrant, which was farthest from
the hidden platform located before. The number of platform
crossings and the latency to reach the previous platform location
were recorded for comparison.

Data shown are expressed as means ± S.E.M. For multiple
comparisons, data were analyzed using one-way analysis of
variance (ANOVA) followed by a post hoc Dunnett’s test. For
two group’s comparisons, data were analyzed statistically using
Student’s t-test. A p < 0.05 was considered to be significant.

Step-Down Passive Avoidance Test (PA)

RESULTS

The test was carried out utilizing a square chamber within
a wooden platform on one side of the grid floor, which
can receive electric shocks from the isolated pulse stimulator.
The test consists of 3 sessions: habituation, training, and
retention. Preceding the training, mice were first habituated to
the apparatus. During the habituation process, the mice were
separately placed on the platform. Once their feet were fully
exposed to the grid floor, mice were subjected to a foot shock
(0.4–0.8 mA, 40 V, 0.5 s, 50 Hz, 20 s intertribal interval). The
training test repeated the habituation procedure after 1 h. Mice
were considered to have taken in the task when they stayed
on the platform for over 60 s. Retention tests were conducted 3
and 24 h after the training session. During the retention session,

The Effects of Aβ1-42 on Spatial Learning
and Memory in the MWM at 1 W, 2 M,
and 6 M

Frontiers in Aging Neuroscience | www.frontiersin.org

Statistical Analysis

As shown in Figure 1, intracerebroventricular injection of Aβ142 altered the learning ability of mice in the MWM as compared
with control animals at 1 W, 2 M, and 6 M. There were no
significant differences in mean latency time in the initial training
block at any time point (Figure 1A–C). Animals treated with
Aβ1-42 at 1 W prior to the test exhibited partial reduction
in learning in MWM, as was demonstrated by significantly
increased mean latency to platform from block 3 to block 6
(p < 0.01, p < 0.05, p < 0.05, p < 0.01, Figure 1A). The most
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FIGURE 1 | Aβ1-42 induced spatial memory impairment in the Morris water maze task at 1 week, 2 and 6 months after intracerebroventricular microinjection of
Aβ1-42. During the acquisition trials of the water maze task, learning curve were tested after intracerebroventricular microinjection of Aβ1-42 1 week (A), 2 months
(B), and 6 months (C). The probe trial was conducted 1 and 24 h after training, the latency to reach the platform (D,F) and the number of platform crossings
(E,G) were determined. Values shown are means ± SEM, n = 10; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. vehicle-treated control group.

as compared with the vehicle-treated animals (p’s < 0.001,
Figure 1G). Swimming speed also did not change (data not
shown).

prominent learning impairment was found at 2 M, in which the
latency to platform was significantly longer from block 2 to block
6 (p < 0.01, p’s < 0.001, Figure 1B). At 6 M, the Aβ-treated
animals did not exhibit significantly increased latency to platform
as compared with those of controls. Swimming speed did not
change (data not shown).
Figures 1D,E presented the data on short-term memory.
At each time point, i.e., 1 W, 2 M, and 6 M, 1 h after
training, the hidden platform was removed and the probe
trial was conducted. The results showed that Aβ1-42-treated
mice exhibited increased latencies to platform at 1 W and 2 M
(p’s < 0.001, Figure 1D). At the same time points, platform
crossings were also significantly reduced in the Aβ1-42-treated
mice as compared with the vehicle-treated mice (p’s < 0.001,
Figure 1E). The results of Figures 1F,G were from the 24 h probe
trial, which was used for examining the long-term memory. The
data showed that Aβ1-42-treated animals exhibited increased
latencies to platform at 1 W and 2 M (p’s < 0.001, Figure 1F);
and at all the time points, i.e., 1 W, 2 M and 6 M, Aβ1-42treated mice exhibited reduced number of platform crossings

Frontiers in Aging Neuroscience | www.frontiersin.org

The Effects of Aβ1-42 on Memory
Retention in the Step-Down Passive
Avoidance Test at 1 W, 2 M, and 6 M
The memory retention measured by the latency to jump off the
platform was determined 3 and 24 h after the training session in
the step-down passive avoidance test after the mice were treated
with Aβ1-42 at different time periods, i.e., 1 W, 2 M, and 6 M,
as shown in Figure 2. The results suggested that the short-term
memory retention (3 h after training session) was significantly
decreased after the treatment with Aβ1-42 at 1 W and 2 M
when compared with vehicle-treated control groups (p’s < 0.001,
Figure 2A), which peaked at 2 M. However, the change was not
significant 6 M after Aβ1-42 treatment. For long-term memory
(24 h after training session), the differences of latency to the
previous platform location were kept significant at 1 W, 2 M,

4

July 2018 | Volume 10 | Article 204

Xu et al.

Inhibitory PDE4 Reverses Memory Impairment

FIGURE 2 | Aβ1-42 induced memory impairment in the step-down passive avoidance test at 1 week, 2 and 6 months after intracerebroventricular microinjection of
Aβ1-42. Retention tests were conducted 3 (A) and 24 h (B) after the training session. Values shown are means ± SEM, n = 10; *p < 0.05 and ***p < 0.001 vs.
vehicle-treated control group.

FIGURE 3 | The effects of rolipram on Aβ1-42-induced memory impairment in the Morris water-maze test in mice. One and a half months after microinfusion with
Aβ1-42 into cerebroventricle, mice were administrated with rolipram for 14 days. H89 and KT5823 were pretreated 30 min before rolipram administration every day.
During the acquisition trials of the water maze task, learning curve was tested 24 h after last treatment with rolipram (A,B). The probe trial was conducted 1 and 24 h
after training, the latency to reach the platform (C,E) and the number of platform crossings (D,F) were determined. Values shown are means ± SEM, n = 10;
**p < 0.01 and ***p < 0.001 vs. vehicle treated sham group. # p < 0.05, ## p < 0.01, and ### p < 0.001 vs. vehicle-treated Aβ group. $$ P < 0.01 and
$$$ P < 0.001 vs. rolipram (1.0 mg/kg)-treated Aβ group.
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doses of rolipram (1.0 mg/kg) on both short-term and longterm memories was blocked by the pretreatment with H89
(p’s < 0.001), but not KT5823. Swimming speed also did not
change (data not shown).
Rolipram-induced memory enhancement was supported by
the step-down passive avoidance test, as shown in Figure 4.
Treatment of Aβ1-42 induced a significant decrease in step-down
latency (the latency to jump off the platform) both 3 and 24 h
after training session (p’s < 0.001, Figures 4A,B). Treatment of
rolipram (0.1, 0.5, and 1.0 mg/kg, i.p.) for 14 days significantly
enhanced the memory retention [F (3, 36) = 20.86, p < 0.001,
Figure 4A; F (3, 36) = 22.93, p < 0.001, Figure 4B]. However,
PKA inhibitor H89 reversed the effects of rolipram on step-down
latency significantly (1.0 mg/kg for 14 days) [F (2, 27) = 41.70,
p < 0.001, Figure 4A; F (2, 27) = 34.60, p < 0.001, Figure 4B],
whereas PKG inhibitor did not show such effects. Neither H89
nor KT5823 used alone showed any effects in MWM and PA in
mice treated with Aβ1-42 (Supplementary Figures 1A–G).

and 6 M after Aβ1-42 treatment as compared with vehicle-treated
control groups (p < 0.001; p < 0.05; Figure 2B).

Rolipram Reversed the Aβ-Induced
Memory Impairment in the MWM and PA
Tests
Since serious memory impairment was found at 2 months after
treatment with Aβ1-42, the following behavioral and biological
assays were performed at this time point. During 6 blocks of
training sessions in the MWM, the Aβ-treated mice presented an
increase in mean latency to reach the platform from block 4 to
6 as compared with the vehicle-treated control group (p’s < 0.01,
p < 0.001, Figure 3A). Chronic rolipram administration (0.1, 0.5,
and 1.0 mg/kg for 14 days) significantly reduced the mean latency
to the platform from block 5 to 6 in Aβ1-42-treated mice, in a
dose-dependent manner [F (3, 36) = 30.22, p < 0.001]. However,
these effects of rolipram on acquisition of memory, shown as the
learning curve, were inhibited by the PKA inhibitor H89, which
was administered 30 min before rolipram (p’s < 0.01; Figure 3B).
Meanwhile, Pretreatment with the PKG inhibitor KT5823 did
not show such effects. Swimming speed did not change (data not
shown).
The probe trial test was conducted 1 h after the last training
session to assess the short-term spatial memory. The results
suggested that Aβ1-42, administered 2 months prior to the
MWM test, increased the latency to the previous platform
location and decreased the number of platform crossings
as compared with the vehicle-treated controls (p’s < 0.001,
Figures 3C,D). These effects were reversed by rolipram at doses
of 0.5 and 1.0 mg/kg (i.p.) (p’s < 0.001). Long-term spatial
memory was also determined in the probe trial 24 h later.
Memory performance was worse in the Aβ-treated mice, as
indicated by an increased latency time to reach the previous
platform location (p < 0.001, Figure 3E) and fewer platform
crossings (p < 0.001, Figure 3F). Rolipram (0.1, 0.5, and
1.0 mg/kg, i.p.) ameliorated the effect of Aβ1-42 on latency to
platform and platform crossing in a dose-dependent manner
[F (3, 36) = 9.739, p < 0.001, Figure 3E; F (3, 36) = 34.567,
p < 0.001, Figure 3F]. However, the amelioration due to high

Rolipram Reduced the Serum
Corticosterone (CORT) Levels, but Did Not
Change the Ratio of Adrenal Gland to Body
Weight (AG/B)
The effects of chronic administration with rolipram on the AG/B
and serum corticosterone levels in Aβ1-42-treated mice were
summarized in Figure 5. Aβ1-42 administration significantly
increased the ratio of AG/B relative to vehicle-treated controls
(p < 0.01). Rolipram (0.1, 0.5, and 1.0 mg/kg, i.p.) did not
induce any changes in this ratio [F (3, 36) = 0.961, p > 0.05,
Figure 4A]. However, Aβ1-42 microinjection resulted in a
significant elevation of serum CORT level (P < 0.001, Figure 5B).
Rolipram (0.1, 0.5, and 1.0 mg/kg) significantly reduced the
Aβ1-42-induced increase in CORT level compared to vehicletreated Aβ1-42 group [F (3, 36) = 26.43, p’s < 0.001]. However,
pretreatment with H89 partially prevented the reduction of
serum CORT level induced by high dose of rolipram at 1.0 mg/kg
(p < 0.05), whereas KT5823 did not have such positive effects.
H89 and KT5823 used alone did not show any specific effects on
CORT level (Supplementary Figure 1H).

FIGURE 4 | The effects of rolipram on 3-h (A) and 24-h (B) memory retention in the step-down passive avoidance test in Aβ42-treated mice. Aβ42-induced
decreases in 3-h and 24-h retention were reversed by chronic treatment with rolipram for 14 days Values shown are means ± SEM, n = 10; ***p < 0.001 vs.
vehicle-treated control group. ### p < 0.001 vs. vehicle-treated Aβ group. $$$ p < 0.001 vs. rolipram (1.0 mg/kg)-treated Aβ group.
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Rolipram Reversed the Aβ-Induced
Increases in CRF Receptor and GR
Expression in the Hippocampus and Cortex

Treatment with rolipram (0.1, 0.5, and 1.0 mg/kg, i.p.) for 2
weeks significantly decreased CRF receptor expression both
in the hippocampus [F (3, 36) = 5.64, p < 0.01] and cortex
[F (3, 36) = 5.59, p < 0.01] regions, which were blocked by
pretreatment of H89 (p < 0.001; p < 0.01), but not KT5823.
Similarly, GR levels increased in the hippocampus and cortex
in Aβ-treated mice (p < 0.05; p < 0.01, Figures 6C,D). This

The expression of CRF receptor in Aβ-treated mice increased in
the hippocampus and cortex regions when compared with the
respective control groups (p < 0.001, p < 0.01, Figures 6A,B).

FIGURE 5 | The effects of rolipram on the ratio of adrenal gland weight to body weight (AG/B) (mg/g) (A) and serum corticosterone level (B) in Aβ42-treated mice.
Values shown are means ± SEM, n = 10; **p < 0.01 and ***p < 0.001 vs. vehicle-treated control group. ### p < 0.001 vs. vehicle-treated Aβ group. $ p < 0.05 vs.
rolipram (1.0 mg/kg)-treated Aβ group.

FIGURE 6 | The effects of rolipram on Aβ-induced changes in CRF receptor and GR expression in the hippocampus (A,C) and in the cortex (B,D) of mice. Values
shown are means ± SEM, n = 10; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. vehicle-treated control group. # p < 0.05, ## p < 0.01 and ### p < 0.001 vs.
vehicle-treated Aβ group. $$ p < 0.01 and $$$ p < 0.001 vs. rolipram (1.0 mg/kg)-treated Aβ group.

Frontiers in Aging Neuroscience | www.frontiersin.org

7

July 2018 | Volume 10 | Article 204

Xu et al.

Inhibitory PDE4 Reverses Memory Impairment

The significant decreases in BDNF levels in both the
hippocampus and cortex regions were observed after treatment
with Aβ1-42 (p < 0.01; p < 0.001; Figures 7C,D). Rolipram
at 0.5 and 1.0 mg/kg (i.p.) significantly increased the BDNF
levels in both hippocampus (p < 0.05, p < 0.001) and cortex
(p’s < 0.001). H89 reversed the effects of rolipram on BDNF
expression in both of the hippocampus and cortex regions
(p < 0.001; p < 0.001). Both H89 and KT5823 used alone did
not show any influence on pCREB/CREB and BDNF expressions
(Supplementary Figures 2E–H).
Figure 8 summarizes the effects of rolipram on Aβ1-42induced learning and memory impairments and the related
signaling pathway.

Aβ1-42-induced increase in GR was significantly blocked by
chronic treatment with rolipram at doses of 0.1, 0.5, and
1.0 mg/kg in the hippocampus [F (3, 36) = 9.85, p < 0.01] and
cortex [F (3, 36) = 13.85, p < 0.001]. However, H89 inhibited the
rolipram’s effects on GR expression in these two brain regions
(p < 0.01; p < 0.001). Both H89 and KT5823 used alone
did not show any effects on CRF receptor and GR expression
(Supplementary Figures 2A–D).

Rolipram Reversed the Aβ-Induced
Decreases in pCREB/CREB and BDNF
Expression in the Hippocampus and Cortex
As shown in Figures 7A,B, the reduction of pCREB/CREB
caused by the treatment of Aβ1-42 for 2 months was found
(p < 0.001 in the hippocampus, p < 0.01 in the cortex). This
reduction was ameliorated by the administration of rolipram for
14 days [F (3, 36) = 3.754, p < 0.05, Figure 7A; F (3, 36) = 3.512,
p < 0.05, Figure 7B]. The PKA inhibitor H89 reversed the 0.5
or 1.0 mg/kg dose of rolipram-induced increase in the ratio of
pCREB to CREB both in the hippocampus and cortex regions
(p < 0.01; p < 0.05).

DISCUSSION
The present study suggested that Aβ1-42 intracerebroventricular
administration caused overall impairment of learning and
memory processes in both of the MWM and PA tests at 1
week, 2 and 6 months after treatment, of which the effect
was most prominent at 2 months. The subsequent studies
demonstrated that the PDE4 inhibitor rolipram was able to

FIGURE 7 | The effects of rolipram on Aβ-induced changes in the ratio of pCREB to CREB and BDNF expression in the hippocampus (A,C) and the cortex (B,D) of
mice. Values shown are means ± SEM, n = 10; **p < 0.01 and ***p < 0.001 vs. vehicle-treated control group. # p < 0.05, ## p < 0.01 and ### p < 0.001 vs.
vehicle-treated Aβ group. $ p < 0.05, $$ p < ,0.01 and $$$ p < 0.001 vs. rolipram (0.5 or 1.0 mg/kg)-treated Aβ group.
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ameliorate Aβ1-42-induced learning and memory impairment by
regulating the HPA axis, leading to increases in cAMP-related
proteins such as the ratio of pCREB/CREB and BDNF expression.
However, these effects were blocked by the PKA inhibitor H89,
but not the PKG inhibitor KT5823. These findings suggested
that rolipram ameliorated the memory impairment through the
regulation of Aβ-induced HPA axis dysfunction and initiated the
downstream cAMP-dependent neuroprotective pathway.
Aβ deposition in the brain regions such as hippocampus and
frontal cortex is considered as an early event in the process
of AD, which involves deterioration in learning and memory
processes (Wang et al., 2016). A large number of studies have
shown that microinfusion of Aβ, particularly Aβ1-42, into
the cerebral ventricle is a reliable model of AD because the
cerebral ventricle is a communicating network of cavities filled
with cerebrospinal fluid (CSF) that transmits messages to other
brain regions such as hippocampus and cortex that regulate
learning and memory processes (Guo et al., 2012; Thorajak
et al., 2017). The Aβ-induced AD animal model mimics the
memory impairment and a variety of other pathological features
in AD patients such as amyloid plaques and neurofibrillary
tangles (Tiraboschi et al., 2004). In the present study, the Morris
water maze and step down passive avoidance tests were used
to test learning and memory performance at 1 week, 2 and
6 months after intracerebroventricular microinjection of Aβ142. The results demonstrated that the animals started to show

reduced learning and memory performance in both tests 1 week
after Aβ administration; the effect peaked at 2 months after
treatment and lasted for at least 6 months. Two reasons may
explain this phenomenon: (1) Aβ1-42 induced neurotoxicity
would disappear as time goes on; or (2) the adaptive response
to Aβ would be stimulated after 6 months. Accordingly, it is
reliable that the subsequent cognitive behaviors after treatment
with rolipram were conducted at 2 months after microinfusion
of Aβ1-42 into cerebral ventricle.
Our previous studies suggested that microinjection of Aβ
into the CA1 induced decreased second messengers (cAMP and
cGMP) in the hippocampus (Wang L. et al., 2017). As the
enzymes that hydrolyze and inactivate the second messenger
cAMP, PDE4 is found to be associated with memory regulation.
For example, PDE4 inhibitor rolipram is shown to promote
memory formation by increasing the concentration of cAMP
in the brain (Villiger and Dunn, 1981). Aβ-induced learning
and memory impairment and pathological changes including
deficits in cAMP signaling are consistent with the performance
of early stage of AD patients (Matsuzaki et al., 2006). Our
present study suggested that treatment with rolipram (0.1, 0.5,
1.0 mg/kg-d, i.p.) for 2 weeks was able to protect animals against
Aβ-induced MWM deficits, as mice received rolipram learned
faster in the training session, and rolipram treatment restored
memory performance to that of vehicle-treated Aβ mice during
the probe trials. These results were confirmed by PA test, which
suggested that short-term and long-term memory retention was
ameliorated by treatment with rolipram. However, pretreatment
of animals with the PKA inhibitor H89, but not the PKG inhibitor
KT5823, prevented rolipram-induced protective effects, which
supported the notion that the effects of rolipram on enhancing
learning and memory were achieved through regulation of
cAMP signaling. These were consistent with an earlier finding
that the PDE4 inhibitor rolipram selectively inhibited cAMP
hydrolysis and upregulated PKA levels (Wang et al., 2014). It
was noted in the present study that rolipram started to treat
1.5 months after Aβ1-42 microinjection, in which memory
impairment or dementia was getting worse in animals. Moreover,
rolipram was shown to improve both short-term and longterm memory, which is different from the past studies in which
rolipram primarily enhanced long-term memory (Wang et al.,
2012). It is widely accepted that activating the cAMP-dependent
pathway might ameliorate hippocampus-dependent long-term
memory consolidation (Richter et al., 2013). Indeed, short-term
memory is primarily dependent on regions of the prefrontal
cortex, whereas the consolidation of information from shortterm memory to long-term memory depends on the function
of hippocampus (Cohen, 2011; Serences, 2016). In the present
study, Aβ1-42 was microinjected into the cerebral ventricle,
which permitted Aβ1-42 to transmit messages to various brain
regions including hippocampus and cortex that make it possible
to impair both short-term and long-term memory processes.
Inhibition of PDE4 by intraperitoneal injection might be able
to upregulate cAMP signaling in the cortex and hippocampus,
which is considered to have impact on both short-term and longterm memory. Moreover, the fact that rolipram regulates the HPA
axis dysfunction is also important to enhance short-term memory

FIGURE 8 | Molecular mechanisms describe the Aβ-induced vicious circle.
Aβ1-42 induces HPA axis hyperactivity and decreases the cAMP level, leading
to abnormalities in downstream molecules, i.e., decreased phosphorylation of
CREB and BDNF expression, which in turn to deteriorate learning and memory
disorders. However, Inhibition of PDE4 increases cAMP level and stimulates
HPA axis negative feedback regulation, resulting in decreases in CORT
releasing and CRF receptor and GR expression.
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(Anderson et al., 2014). Therefore, the present results support
the hypothesis that inhibition of PDE4 reversed the memory
impairment induced by Aβ1-42.
The neuroendocrine disorders such as abnormal
glucocorticoids (GCs) levels in AD patients have been reported
in previous studies (Landfield et al., 2007; Brureau et al., 2013).
The up-regulation of GCs in AD animal model potentially leads
to HPA axis dysfunction and aggravates the AD process. Indeed,
dysfunction of HPA axis such as abnormalities in CORT secretion
has been linked to the changes in CNS disorders, particularly
learning and memory impairments (Dong et al., 2008). Previous
in vitro studies suggested that corticotrophin (ACTH) from
pituitary cells appears to be regulated by a cAMP/PKA-mediated
pathway (Hadley et al., 1996; Vargas et al., 2001). In the present
study, we found that excessive CORT releasing stimulated by
Aβ1-42 was rescued by treatment of rolipram for 2 weeks, which
was consistent with the previous studies that suggested rolipram
inhibited the GR function, whereas PKA activator 8-Br-cAMP
increased the GR transcription and function (Dong et al., 1989;
Carvalho et al., 2010). Interestingly, H89 significantly blocked
the rolipram’s effects on CORT releasing, which supports that
the effects of rolipram on regulating the HPA axis is mediated
through the cAMP-PKA-dependent mechanism (Jindal et al.,
2015).
CRF is widely expressed in brain regions and in the types
of neuronal populations that are involved in the regulation of
cognition, emotion and endocrine function (Regev and Baram,
2014). Increased CRF and corticosterone, in turn, stimulates
more Aβ releasing from neurons, which induces deleterious
effects on the structure and function of various brain structures
such as cortex and hippocampus, leading to deterioration of
learning and memory as seen in both animal models and patients
with AD (Guo et al., 2012). Corticosterone and CRF easily cross
the blood-brain barrier and then bind to their receptors in
the brain. The CRF receptor and GR spread all over the brain
regions, particularly the hippocampus and the prefrontal cortex,
which are involved in negative feedback response of HPA axis.
The present study found that rolipram negatively regulated CRF
receptor and GR abnormalities in the hippocampus and cortex
caused by intraventricular administration of Aβ1-42. Subsequent
studies suggested that PKA inhibitor blocked the effects of
rolipram on GR and CRF receptor expression, supporting the
hypothesis that rolipram could regulate HPA axis through cAMP
signaling.
CREB is being considered as a possible therapeutic target for
AD. The aggregation of Aβ suppressed the phosphorylation of
CREB-mediated signaling in mouse model of AD (Xu et al.,
2006), thereby affecting the transcription of genes related to

neuronal plasticity and survival, such as BDNF (Pugazhenthi
et al., 2011; Xu et al., 2013). Down-regulation of BDNF
mediates the toxic effects of prolonged GR activation on
neuronal survival and disrupts the normal expression of CRF
receptor (Jeanneteau and Chao, 2013; Wang R. et al., 2017),
which deteriorate Aβ toxicity. The pathological basis of AD
offers a therapeutic opportunity by enhancing the cAMP-related
signaling, leading to correction of negative feedback of HPA axis
(Zhang et al., 2015). In the present study, Aβ-induced decreases
in the ratio of pCREB/CREB and BDNF expression both in
the hippocampus and cortex, which were rescued by PDE4
inhibitor rolipram. However, these effects were blocked by H89,
but not KT5823, further supporting that cAMP-pCREB-BDNF
pathway is involved in rolipram’s effects on Aβ-induced memory
deficits. The proposed molecular mechanism was summarized in
Figure 8.
Taken together, the present study suggested that learning
and memory impairments were found from 1 week and it
became worst at 2 months after microinjection of Aβ1-42 to the
cerebral ventricle. Treatment with the PDE4 inhibitor rolipram
for 2 weeks significantly ameliorated the learning and memory
deficits. These effects of rolipram might involve the regulation
of HPA axis and the downstream cAMP-pCREB-BDNF
signaling.

AUTHOR CONTRIBUTIONS
YX, NZ, and WX wrote the manuscript and did a part of
the behavioral tests. HY, KL, FW, MZ, and YD performed
the biochemical and neurobiological experiments. CZ analyzed
the data. JO and HZ revised the manuscript. JP designed and
supervised the manuscript.

ACKNOWLEDGMENTS
This study was supported by the Natural Science Foundation
of Zhejiang Province in China (LY14H310012) to JP; 2015
American Association of Colleges of Pharmacy New Investigator
Award and Innovative Micro-Programs Accelerating
Collaboration in Themes (IMPACT) to YX.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fnagi.
2018.00204/full#supplementary-material
Supplementary Figures 1 and 2 | The effects of H89 and KT5823 used alone
on Aβ-induced cognitive impairment.

REFERENCES

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and
Jones, E. (2011). Alzheimer’s disease. Lancet 377, 1019–1031.
doi: 10.1016/S0140-6736(10)61349-9
Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer’s disease. Lancet
368, 387–403. doi: 10.1016/S0140-6736(06)69113-7
Brureau, A., Zussy, C., Delair, B., Ogier, C., Ixart, G., Maurice, T., et al.
(2013). Deregulation of hypothalamic-pituitary-adrenal axis functions

Anderson, R. M., Birnie, A. K., Koblesky, N. K., Romig-Martin, S. A.,
and Radley, J. J. (2014). Adrenocortical status predicts the degree
of age-related deficits in prefrontal structural plasticity and working
memory. J. Neurosci. 34, 8387–8397. doi: 10.1523/JNEUROSCI.1385-1
4.2014

Frontiers in Aging Neuroscience | www.frontiersin.org

10

July 2018 | Volume 10 | Article 204

Xu et al.

Inhibitory PDE4 Reverses Memory Impairment

Ther.
Targets
17,
1011–1027.
doi:
10.1517/14728222.2013.
818656
Serences, J. T. (2016). Neural mechanisms of information storage in visual shortterm memory. Vision Res. 128, 53–67. doi: 10.1016/j.visres.2016.09.010
Thorajak, P., Pannangrong, W., Welbat, J. U., Chaijaroonkhanarak, W.,
Sripanidkulchai, K., and Sripanidkulchai, B. (2017). Effects of Aged
garlic extract on cholinergic, glutamatergic and GABAergic systems with
regard to cognitive impairment in abeta-induced rats. Nutrients 9:E686.
doi: 10.3390/nu9070686
Tiraboschi, P., Hansen, L. A., Thal, L. J., and Corey-Bloom, J. (2004). The
importance of neuritic plaques and tangles to the development and evolution
of AD. Neurology 62, 1984–1989. doi: 10.1212/01.wnl.0000129697.01779.0a
Vargas, M. L., Abella, C., and Hernandez, J. (2001). Diazepam increases
the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a
cyclic AMP-dependent mechanism. Br. J. Pharmacol. 133, 1355–1361.
doi: 10.1038/sj.bjp.0704201
Villiger, J. W., and Dunn, A. J. (1981). Phosphodiesterase inhibitors facilitate
memory for passive avoidance conditioning. Behav. Neural Biol. 31, 354–359.
doi: 10.1016/s0163-1047(81)91424-2
Wang, C., Yang, X. M., Zhuo, Y. Y., Zhou, H., Lin, H. B., Cheng, Y. F., et al. (2012).
The phosphodiesterase-4 inhibitor rolipram reverses Abeta-induced cognitive
impairment and neuroinflammatory and apoptotic responses in rats. Int. J.
Neuropsychopharmacol. 15, 749–766. doi: 10.1017/S1461145711000836
Wang, C., Zhang, J., Lu, Y., Lin, P., Pan, T., Zhao, X., et al. (2014).
Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and
phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling
in mice. Metab. Brain Dis. 29, 673–682. doi: 10.1007/s11011-014-9533-4
Wang, G., Chen, L., Pan, X., Chen, J., Wang, L., Wang, W., et al. (2016).
The effect of resveratrol on beta amyloid-induced memory impairment
involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7,
17380–17392. doi: 10.18632/oncotarget.8041
Wang, L., Xiaokaiti, Y., Wang, G., Xu, X., Chen, L., Huang, X., et al. (2017).
Inhibition of PDE2 reverses beta amyloid induced memory impairment
through regulation of PKA/PKG-dependent neuro-inflammatory and
apoptotic pathways. Sci. Rep. 7:12044. doi: 10.1038/s41598-017-08070-2
Wang, R., Yan, F., Liao, R., Wan, P., Little, P. J., and Zheng, W. (2017). Role of
brain-derived neurotrophic factor and nerve growth factor in the regulation
of Neuropeptide W in vitro and in vivo. Mol. Cell. Endocrinol. 447, 71–78.
doi: 10.1016/j.mce.2017.02.040
Xu, Y., Ku, B., Tie, L., Yao, H., Jiang, W., Ma, X., et al. (2006). Curcumin
reverses the effects of chronic stress on behavior, the HPA axis, BDNF
expression and phosphorylation of CREB. Brain Res. 1122, 56–64.
doi: 10.1016/j.brainres.2006.09.009
Xu, Y., Lin, D., Li, S., Li, G., Shyamala, S. G., Barish, P. A., et al. (2009). Curcumin
reverses impaired cognition and neuronal plasticity induced by chronic stress.
Neuropharmacology. 57, 463–471. doi: 10.1016/j.neuropharm.2009.06.010
Xu, Y., Pan, J., Chen, L., Zhang, C., Sun, J., Li, J., et al. (2013). Phosphodiesterase2 inhibitor reverses corticosterone-induced neurotoxicity and related
behavioural changes via cGMP/PKG dependent pathway. Int. J.
Neuropsychopharmacol. 16, 835–847. doi: 10.1017/S146114571200065X
Xu, Y., Pan, J., Sun, J., Ding, L., Ruan, L., Reed, M., et al. (2015).
Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal
remodeling caused by chronic stress. Neurobiol. Aging 36, 955–970.
doi: 10.1016/j.neurobiolaging.2014.08.028
Zhang, C., Yu, Y., Ruan, L., Wang, C., Pan, J., Klabnik, J., et al. (2015). The roles
of phosphodiesterase 2 in the central nervous and peripheral systems. Curr.
Pharm. Des. 21, 274–290. doi: 10.2174/1381612820666140826115245

in an Alzheimer’s disease rat model. Neurobiol. Aging 34, 1426–1439.
doi: 10.1016/j.neurobiolaging.2012.11.015
Carvalho, L. A., Garner, B. A., Dew, T., Fazakerley, H., and Pariantea, C.
M. (2010). Antidepressants, but not antipsychotics, modulate GR function
in human whole blood: an insight into molecular mechanisms. Eur.
Neuropsychopharmacol. 20, 379–387. doi: 10.1016/j.euroneuro.2010.02.006
Chen, Q., Prior, M., Dargusch, R., Roberts, A., Riek, R., Eichmann, C., et al. (2011).
A novel neurotrophic drug for cognitive enhancement and Alzheimer’s disease.
PLoS ONE 6:e27865. doi: 10.1371/journal.pone.0027865
Cheng, Y. F., Wang, C., Lin, H. B., Li, Y. F., Huang, Y., Xu, J. P., et al. (2010).
Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ2535 or Abeta1-40 peptide in rats. Psychopharmacology (Berl) 212, 181–191.
doi: 10.1007/s00213-010-1943-3
Cohen, M. X. (2011). Hippocampal-prefrontal connectivity predicts midfrontal
oscillations and long-term memory performance. Curr. Biol. 21, 1900–1905.
doi: 10.1016/j.cub.2011.09.036
Dong, H., Yuede, C. M., Yoo, H. S., Martin, M. V., Deal, C., Mace, A. G., et al.
(2008). Corticosterone and related receptor expression are associated with
increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience 155,
154–163. doi: 10.1016/j.neuroscience.2008.05.017
Dong, Y., Aronsson, M., Gustafsson, J. A., and Okret, S. (1989). The mechanism
of cAMP-induced glucocorticoid receptor expression. Correlation to cellular
glucocorticoid response. J. Biol. Chem. 264, 13679–13683.
Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., and LaFerla,
F. M. (2006). Glucocorticoids increase amyloid-beta and tau pathology
in a mouse model of Alzheimer’s disease. J. Neurosci. 26, 9047–9056.
doi: 10.1523/JNEUROSCI.2797-06.2006
Guo, Q., Zheng, H., and Justice, N. J. (2012). Central CRF system perturbation in
an Alzheimer’s disease knockin mouse model. Neurobiol. Aging 33, 2678–2691.
doi: 10.1016/j.neurobiolaging.2012.01.002
Hadley, A. J., Kumari, M., Cover, P. O., Osborne, J., Poyser, R., Flack, J. D., et al.
(1996). Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by the
type 4 phosphodiesterase (PDE-4) inhibitor, denbufylline. Br. J. Pharmacol.
119, 463–470. doi: 10.1111/j.1476-5381.1996.tb15695.x
Heckman, P. R., Wouters, C., and Prickaerts, J. (2015). Phosphodiesterase
inhibitors as a target for cognition enhancement in aging and Alzheimer’s
disease: a translational overview. Curr. Pharm. Des. 21, 317–331.
doi: 10.2174/1381612820666140826114601
Jeanneteau, F., and Chao, M. V. (2013). Are BDNF and glucocorticoid activities
calibrated? Neuroscience 239, 173–195. doi: 10.1016/j.neuroscience.2012.09.017
Jindal, A., Mahesh, R., and Bhatt, S. (2015). Type 4 phosphodiesterase enzyme
inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models
of depression: involvement of hypothalamic-pituitary-adrenal axis, cAMP
signaling aspects and antioxidant defense system. Pharmacol. Biochem. Behav.
132, 20–32. doi: 10.1016/j.pbb.2015.02.017
Landfield, P. W., Blalock, E. M., Chen, K. C., and Porter, N. M. (2007). A new
glucocorticoid hypothesis of brain aging: implications for Alzheimer’s disease.
Curr. Alzheimer Res. 4, 205–212. doi: 10.2174/156720507780362083
Lueptow, L. M., Zhan, C. G., and O’Donnell, J. M. (2016). Cyclic GMPmediated memory enhancement in the object recognition test by inhibitors
of phosphodiesterase-2 in mice. Psychopharmacology (Berl) 233, 447–456.
doi: 10.1007/s00213-015-4129-1
Matsuzaki, K., Yamakuni, T., Hashimoto, M., Haque, A. M., Shido, O.,
Mimaki, Y., et al. (2006). Nobiletin restoring beta-amyloid-impaired CREB
phosphorylation rescues memory deterioration in Alzheimer’s disease model
rats. Neurosci. Lett. 400, 230–234. doi: 10.1016/j.neulet.2006.02.077
Nasehi, M., Sharifi, S., and Zarrindast, M. R. (2012). Involvement of
the cholinergic system of CA1 on harmane-induced amnesia in the
step-down passive avoidance test. J. Psychopharmacol. 26, 1151–1161.
doi: 10.1177/0269881111421972
Pugazhenthi, S., Wang, M., Pham, S., Sze, C. I., and Eckman, C. B.
(2011). Downregulation of CREB expression in Alzheimer’s brain and
in Abeta-treated rat hippocampal neurons. Mol. Neurodegener. 6:60.
doi: 10.1186/1750-1326-6-60
Regev, L., and Baram, T. Z. (2014). Corticotropin releasing
factor in neuroplasticity. Front. Neuroendocrinol. 35, 171–179.
doi: 10.1016/j.yfrne.2013.10.001
Richter, W., Menniti, F. S., Zhang, H. T., and Conti, M. (2013).
PDE4 as a target for cognition enhancement. Expert Opin.

Frontiers in Aging Neuroscience | www.frontiersin.org

Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Xu, Zhu, Xu, Ye, Liu, Wu, Zhang, Ding, Zhang, Zhang, O’Donnell
and Pan. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.

11

July 2018 | Volume 10 | Article 204

